Reply  by Quinones-Baldrich, William J.
LETTERS TO THE EDITOR
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tRegarding “Outcomes of percutaneous endovascular
intervention for type II endoleak with aneurysm
expansion”
I read with much interest the article “Outcomes of percutaneous
endovascular intervention for type II endoleak with aneurysm expan-
sion,” which appeared in the May issue of the Journal.1 I would like to
point out that the authors have wrongly specified our technique as a
post-endovascular aneurysm repair (EVAR) operative approach.2
Our technique is a preventive technique performed during
EVAR and not a post-EVAR operative approach. As we wrote in
two other articles,3,4 natural history and our experience in the
treatment of type II endoleaks led us to investigate prevention as
the best strategy in managing this complication.
Intrasac biomaterial insertion stimulates clot formation excluding
the aortic collateral branches and stabilizing the entire complex en
bloc. This technique is quick and safe, regardless of the stent graft
used. In our experience, it is effective in significantly reducing the
incidence of type II endoleak even in follow-up beyond 1 year.5
Salvatore Ronsivalle, MD
Vascular and Endovascular Surgery and Angiology
Cittadella Hospital
Padua, Italy
REFERENCES
1. Aziz A, Menias CO, Sanchez LA, Picus D, Saad N, Rubin BG, et al.
Outcomes of percutaneous endovascular intervention for type II en-
doleak with aneurysm expansion. J Vasc Surg 2012;55:1263-7.
2. Zanchetta M, Faresin F, Pedon L, Riggi M, Ronsivalle S. Fibrin glue
aneurysm sac embolization at the time of endografting. J Endovasc Ther
2005;12:579-82.
3. Zanchetta M, Faresin F, Pedon L, Ronsivalle S. Intraoperative intrasac
thrombin injection to prevent type II endoleak after endovascular ab-
dominal aortic aneurysm repair. J Endovasc Ther 2007;14:176-83.
4. Ronsivalle S, Faresin F, Franz F, Rettore C, Zanchetta M, Olivieri A.
Aneurysm sac “thrombization” and stabilization in EVAR: a technique
to reduce the risk of type II endoleak. J Endovasc Ther 2010;17:517-24.
5. Ronsivalle S, Faresin F, Franz F, Rettore C, Zanchetta M, Olivieri A.
Type II endoleak: from treatment of a complication to prevention. J
Endovasc Ther 2012;19:128-30.
http://dx.doi.org/10.1016/j.jvs.2012.06.080
Regarding “Inferior vena cava resection and
reconstruction for retroperitoneal tumor excision”
The authors report their surgical experience of inferior vena cava
(IVC) resection and reconstruction for patients with retroperitoneal
tumor excision.1 Of the 47 patients included in the study, 27 patients
underwent circumferential resection of the IVC and replacement with
polytetrafluoroethylene (PTFE) graft after en bloc tumor resection.
Eighteen of these patients underwent extensive resection and replace-
ment of the IVC. We would like to commend the authors for their
excellent surgical technique and the postoperative results.
We have encountered similar situations in the management of
patients with advanced renal cell cancer extending into the IVC.2 To
resect the entire tumor, excision of the affected portion of the IVC was
required in several instances.3,4 A significant proportion of these
patients presented with complete obstruction of the IVC with tumor
thrombus. From our practice, it may not be necessary to reconstruct
the IVC in patients with complete obstruction with established col-
lateralization. A natural venovenous bypass evolves from the collateral
c
o
1198eins created by the obstruction of the IVC.5 We have previously
eported on a total of nine patients who had complete obstruction of
he IVC and underwent IVC resection without reconstruction.3,4 In
ost of our cases, IVC clamping above and below the tumor throm-
us did not result in systemic hypotension due to adequate natural
ollateralization. The major concerns of interrupting the IVC are
orbidity associated with venous congestion and lymphatic extrava-
ation causing third space retention. Generally, in patients with
hronic occlusion of the IVC without evidence of preoperative lower
xtremity edema, these complications are well tolerated. The benefits
f not reconstructing the IVC are noteworthy and include reductions
n operative time, avoidance of graft infections, and potential lifelong
nticoagulation.6
Finally, the authors have described their approach for replace-
ent of the retrohepatic IVC with the outflow control below and
bove the liver.1 In patients with renal cell carcinoma, we have
ncountered similar situations where the thrombus invades to the
oint of the retrohepatic IVC. We have obtained vascular control
f the retrohepatic segment of the IVC using the “piggyback” liver
obilization technique, which eliminates the need of hepatic
ascular isolation.1,2,4 Mobilization of the IVC from the abdomi-
al wall is a key step for the IVC reconstruction. This technique
ay be selectively utilized in retrohepatic IVC replacements.2
hivam Joshi, MD
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ohn Shields, MD
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Important issues are raised in your letter. Our report of 47
atients with retroperitoneal tumors, the majority of which were
arcomas, undergoing radical resection with vena cava reconstruc-
ion specifically excluded patients with renal cell carcinoma.1 Renal
ell carcinomas with involvement of the inferior vena cava most
ften can be resected with limited inferior vena cava excision and
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Volume 56, Number 4 Letters to the Editor 1199extraction of unattached intraluminal tumor thrombus. Retroper-
itoneal sarcomas with inferior vena cava origin or invasion on the
other hand, require more extensive resection.
Reconstruction of the inferior vena cava after resection as
noted by our experience can be performed with minimal morbidity
and mortality. Operative time is not significantly increased (aver-
ages 4 hours for the entire case) and no graft infections have
occurred in our series. As mentioned in our report, we do not
routinely anticoagulate patients postoperatively even when cir-
cumferential resection and reconstruction have been performed.
The main benefit of inferior vena cava reconstruction is the avoid-
ance of venous hypertension and its clinical manifestations. Ve-
nous collaterals are often removed during radical tumor exci-
sion. In the experience reported by Dylami et al2 with routine
vena cava ligation after resection in six patients, three patients
developed lower extremity edema (reported as “well toler-
ated”), three patients developed acute renal failure with recov-
ery, and two patients developed a chylous leak (potentially
secondary to venous hypertension).
The technique for retrohepatic inferior vena cava exposure,
control and resection as described by Ciancio et al3,4 and referred
to as the “piggyback” method includes control of the portal triad
(Pringle maneuver), mobilization of the retrohepatic inferior vena
cava and ligation of the smaller hepatic veins draining the caudate
lobe. In our cases, more cephalad inferior vena cava involvement
requiring resection and reconstruction (as opposed to removal of
tumor thrombus) of the portion where the main hepatic veins
drain, does require control of the infra- and suprahepatic vena cava.
We refer to this method as “hepatic vascular isolation.” Both
methods involve some degree of liver ischemia and avoid individual
control of the main hepatic veins which are easily injured and
difficult to repair.
Management of tumors involving the inferior vena cava will
differ according to the type of tumor and the degree of invasion of
the vessel wall. Caval reconstruction after resection is associated
with excellent clinical outcomes. We appreciate the opportunity to
clarify these issues.
William J. Quinones-Baldrich, MD
Division of Vascular Surgery
David Geffen School of Medicine at UCLA
UCLA Medical Center
Los Angeles, Calif
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Regarding “Outcomes and practice patterns in
patients undergoing lower extremity bypass”
We read with great interest the recent report by Simons et al,1
which reviewed the Vascular Study Group of New England (VSGNE)
database and analyzed 2907 bypass procedures performed between h003 and 2009 (797 for intermittent claudication [IC], 2110 for
ritical limb ischemia [CLI]) and found that there was a significant
ncrease over time in the proportion of lower extremity bypass (LEB)
rocedures performed after a previous endovascular intervention,
oth in patients with CLI (11%-24%; P  .001) and ICs (13%-23%,
 .02). They found that there was no significant change in the
mputation-free survival (AFS) in patients at 1 year in both IC and
LI subgroups, although the AFS seemed to have a trend for being
etter in 2008 (81% AFS in 2008 vs 73% in 2003; P .10). They also
oted that major amputation steadily decreased in CLI patients from
5.4% in 2003 to 11.0% in 2008, while the graft patency remained
imilar in both IC and CLI patients. The authors appropriately con-
luded that the AFS remained excellent, despite significant increase in
he proportion of patients who had prior endovascular interventions.
We were interested to see how the authors compromised these
ndings with their previous report in 2011,2 however, were surprised
hat this issue was not included in their discussion, and their previous
ork was not among the chosen 10 references for their article. In this
eport, they analyzed the same database for the same time period
2003-2009) and included 1880 patients who had LEBs for CLI.
hey found that the 1-year major amputation and graft occlusion
ates were significantly higher in patients who had prior ipsilateral
eripheral endovascular intervention than those without (31% vs 20%,
 .046; 28% vs 18%, P  .009). Although the impact of previous
ypasses also had poorer outcomes than those without (29% vs 20%
-year major amputation, P  .022; 33% vs 18% 1-year graft occlu-
ion, P .001), they elected to emphasize the poorer outcomes after
ndovascular interventions, by choosing to title their work “Prior
ailed ipsilateral percutaneous endovascular intervention predicts poor
utcome after lower extremity bypass.”
As their 2011 work supported the findings of the largely
uoted Bypass versus Angioplasty in Severe Ischaemia of the Leg
BASIL) trial suggesting a negative impact of prior endovascular
nterventions on subsequent outcomes following bypass surgery,3
pponents of endovascular first have been quoting these data to
upport their position on the issue, especially for those with good
ein grafts. Therefore, we would be very interested to hear the take
f the authors on their two very different conclusions from the
ame database and understand what exactly does the VSGNE
atabase tell us: Is prior endovascular intervention detrimental or
ot on the outcomes of subsequent bypass procedures in CLI?
asan Haldun Dosluoglu, MD
urandath Lall, MBBS
inda M. Harris, MD
aciej L. Dryjski, MD
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